No Reimbursement, No Revenue: Why MedTech Startups Must Think Beyond FDA

For many MedTech startups, FDA clearance feels like the finish line. In reality, it’s just the beginning.

Too often, companies invest years in product development, regulatory strategy, and clinical validation, only to discover late in the game that there is no clear pathway to coding, coverage, or payment. Without reimbursement, even the most innovative device struggles to generate revenue, secure hospital adoption, or attract follow-on investment.
This webinar will explore why reimbursement strategy must be embedded early in product development, not bolted on after approval. We’ll break down:

  • The difference between regulatory clearance and payer coverage
  • How coding, DRG assignment, and payment mechanisms impact commercial viability
  • The financial risks of delaying reimbursement planning
  • How early payer engagement can de-risk investment and strengthen valuation
  • Practical steps startups can take in the pre-clinical and clinical phases to build a reimbursement-ready evidence strategy

Designed for founders, executive teams, investors, and commercialization leads, this session will provide a clear framework for aligning regulatory, clinical, and market access strategy from day one.

Because in MedTech, approval does not guarantee adoption and innovation without reimbursement doesn’t translate into revenue.
Write your awesome label here.
Lesson series

Don't Miss Out Watch Now!

Write your awesome label here.

Courses